Cargando…
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treat...
Autores principales: | Antonini, Angelo, Calandrella, Daniela |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101890/ https://www.ncbi.nlm.nih.gov/pubmed/21654875 http://dx.doi.org/10.2147/NDT.S10097 |
Ejemplares similares
-
Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008) -
Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008) -
Pramipexole: new use for an old drug – the potential use of pramipexole in the treatment of restless legs syndrome
por: Benbir, Gulcin, et al.
Publicado: (2006) -
Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011) -
Pramipexole and its Extended Release Formulation for Parkinson’s Disease
por: Fishman, Paul S.
Publicado: (2011)